19. November 2009 00:49
Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.
[More]
259b6317-e2c9-41a9-839b-c824711a233a|0|.0
Posted in: Drug Trial News | Pharmaceutical News
Tags: Anti-Inflammatory, Arthritis, Biomarker, Biotechnology, Cardiovascular Disease, Hospital, Macrophage, Rheumatoid Arthritis, Stent, Transplant, Ultrasound, Virus
19. November 2009 00:44
Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED).
[More]
19. November 2009 00:22
Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.
[More]
9f19f465-9b09-4558-8717-5dc5f9c0f5b8|0|.0
Posted in: Drug Trial News | Pharmaceutical News
Tags: Anorexia, Biopsy, Biotechnology, Cancer, Cell, Cell Proliferation, Chemotherapy, Colorectal Cancer, Diarrhea, Erlotinib, Head and Neck Cancer, Hepatocellular Carcinoma, Lung Cancer, Nausea, Non-Small Cell Lung Cancer, Pfizer, Radiotherapy, Small Cell Lung Cancer, Squamous Cell Carcinoma, Vomiting
18. November 2009 10:42
AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.
[More]
18. November 2009 10:31
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
[More]
a61a65ac-e150-48dc-bb4d-d91e79fc3c1c|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abdominal Pain, Anemia, Anorexia, Anxiety, Arthralgia, Blindness, Bone, Cancer, Cell, Constipation, Cough, Dehydration, Diarrhea, Doxorubicin, Dyspnea, Edema, Headache, Heart Failure, Herpes, Herpes Zoster, Hypersensitivity, Insomnia, Liposome, Lymphoma, Multiple Myeloma, Nausea, Neuropathy, Neutropenia, Nursing, Oncology, Peripheral Neuropathy, Pneumonia, Thrombocytopenia, Ubiquitin, Vomiting
18. November 2009 09:34
Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee's Pharmaceutical Holdings, the execution of a collaboration and license agreement for Jennerex's lead product candidate, JX-594, in certain Asian territories.
[More]
18. November 2009 09:14
CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.
[More]
22d7d56a-040a-4b79-b687-06869cbedf35|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anemia, Cancer, Cell, Chemotherapy, Doxorubicin, Dysplasia, Epirubicin, Gastritis, Helicobacter pylori Infection, Investment, Leukemia, Oncology, Smoking, Stomach Cancer, Tobacco
18. November 2009 08:52
Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash.
[More]
18. November 2009 08:40
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.
[More]
7105e9d6-13ab-4fd4-afa9-3e55eccba03a|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Acute Lymphoblastic Leukemia, Apoptosis, Breast Cancer, Cancer, Cell, Chronic Myeloid Leukemia, Colon Cancer, Erlotinib, Gleevec, Hospital, Leukemia, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Myeloid Leukemia, Non-Small Cell Lung Cancer, Oncology, Paclitaxel, Pancreatic Cancer, Prostate Cancer, Small Cell Lung Cancer, Sunitinib, Tarceva, Xenograft
18. November 2009 08:24
CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA.
[More]
18. November 2009 08:13
Clinical Data, Inc. today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart.
[More]
18. November 2009 07:38
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.
[More]
2e16dd3c-6f4f-44b3-9889-330f4bb7656d|0|.0
Posted in: Drug Trial News | Pharmaceutical News
Tags: Blood Vessel, Cancer, Cell, Cell Proliferation, Hepatocellular Carcinoma, Hypercholesterolemia, microRNA, Nanoparticle, Oncology, Physiology, RNAi Therapeutics, siRNA, VEGF, Virus
18. November 2009 07:16
VIVUS, Inc. today announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients.
[More]
18. November 2009 07:06
Genzyme Corporation today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela® (sevelamer carbonate).
[More]
18. November 2009 06:21
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
[More] 
Subscribe